The Phase 3 trial REDEFINE 1 (Garvey et al., 2025) reported a reduction of -20.4 percent versus -3.0 percent on placebo at 68 weeks across n=3417 participants
Koehler et al., 2015) (Table 1)
Thats why semaglutide is often used for type 2 diabetes and medical weight loss
In the study administering Semaglutide at 30 nmol/kg/day ( n = 11 for Vehicle group

Statistical analysis For each study population, the semaglutide cohort and the comparision cohort were propensity-score matched (1:1 using nearest neighbor greedy matching with a caliper of 0.25 times the standard deviation) on covariates that are potential risk factors for AUD 57,58,59,60 including demographics, adverse socioeconomic determinants of health (e.g., problems related to education and literacy, employment and unemployment, housing and economic circumstances, social environment, upbringing, primary support group including family circumstances and various psychosocial circumstances), problems with lifestyle (e.g., tobacco use, lack of physical exercise, inappropriate diet and eating habits, high-risk sexual behavior, gambling and betting, and other problems related to lifestyle including antisocial behaviors and sleep deprivation), pre-existing medical conditions, medications, medical procedures and medical visit types (outpatient, inpatient, emergency, and virtual)